Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.

2.

For patients with breast cancer receiving chemotherapy, exercise may help lessen the long-term side effects.

3.

High levels of traumatic stress found in caregivers of adult cancer patients

4.

Breast cancer-related fatigue: The benefits of adapted physical activity

5.

According to a study, breast cancer in Syrian refugees tends to be diagnosed at an earlier stage and with more advanced tumors.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot